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Introduction
To evaluate the success of any treatment paradigm, it is 
critical to deﬁ  ne the optimal treatment goals in rheu  ma-
toid arthritis (RA) and to determine how achievement 
can be measured.
Treatment goals
Untreated inﬂ  ammation leads to tissue damage; and the 
longer RA is left untreated, the greater the extent of the 
damage [1]. As most joint damage is largely irreversible, 
persistent damage will inevitably result in greater 
disability [1]. Th   e treatment goals in RA therefore include 
[2,3]: prevention or control of joint damage; prevention 
of disease progression; prevention of loss of joint func-
tion; a decrease of symptoms (for example, pain and 
stiﬀ  ness), and achievement of remission or low disease 
activity; improvement in quality of life (QoL) and main-
tenance of lifestyle; achievement of drug-free remission; 
and rapid control of underlying inﬂ  ammation.
Diagnosis and treatment of RA early in the disease 
course provides symptom relief and also prevents long-
term structural damage and functional decline [4], with a 
concomitant improvement in QoL and maintenance of 
everyday activities of daily living. Considering the accep-
ted concept of early treatment in the disease course, a 
window of opportunity may exist whereby therapeutic 
intervention could have a disproportionate impact on 
outcome, resulting in remission induction and mainte-
nance of response after cessation of treatment [5]. Th  e 
ultimate goal of treatment is to achieve drug-free remis-
sion. Previously, despite the fact that drug-free remission 
is the ideal outcome of therapy, remission in patients 
with RA was considered rare and unpredictable at the 
outset of disease [6]. Five-year data from the Behandel-
Strategieën (BeSt) study, however, indicate that 19% of 
patients who received initial combination treatment with 
methotrexate (MTX) and inﬂ  iximab achieved drug-free 
remission [7] – emphasizing that rapid control of 
underlying inﬂ  ammation is critical.
Measures of disease activity
Th  e acute-phase response, a nonspeciﬁ   c reaction to 
inﬂ   ammation, is characterized by an increase in the 
synthesis of certain plasma proteins by the liver, including 
C-reactive protein (CRP), haptoglobin, and α1-antitrypsin 
[8]. Measuring alterations in acute-phase proteins is an 
indirect way of determining the presence and severity of 
inﬂ   ammation [9]. Th  e erythrocyte sedimentation rate 
(ESR) and the CRP level are the most commonly used 
measures of inﬂ  ammation in RA [8].
Increased CRP levels are associated with decreased 
functional ability [10] and with increased disease activity 
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© 2011 BioMed Central Ltdand radiological progression in RA [11,12]. CRP is 
considered a more speciﬁ  c marker of inﬂ  ammation than 
the ESR and also serves as a predictor of functional status 
and joint damage [13]. Additionally, CRP correlates with 
response to therapy as CRP levels lower or normalize in 
RA patients following eﬀ  ective treatment [11]. Although 
CRP is the accepted marker of inﬂ  ammation, the ESR can 
provide useful additional information, particularly 
regard  ing disease severity; routine analyses of both CRP 
and the ESR may therefore be beneﬁ  cial [13].
In terms of remission, deﬁ   nitions that can be used 
include the American Rheumatism Association prelimi-
nary remission criteria and the deﬁ  ned cut-oﬀ   points for 
the disease activity score (DAS), the disease activity score 
in 28 joints (DAS28), the clinical disease activity index, 
and the simpliﬁ  ed disease activity index [14]. Use of the 
DAS to evaluate disease activity in RA (as in several of 
the trials described here) has been extensively validated, 
and current clinical practice is guided by DAS monitoring 
[15,16]. Th   is DAS tool was developed decades ago when 
medications and treatment goals were diﬀ  erent. Some 
suggest that DAS28 remission criteria are not stringent 
enough, and that cut-oﬀ   points for low/moderate/high 
disease activity and remission may in the future need to 
be lower because of more aggressive RA therapy [16].
Furthermore, a Spanish group recently added to the 
body of evidence supporting use of ultrasound for quanti-
fying inﬂ  ammation in RA [17]. Ultrasound with power 
Doppler can be considered an extension of the clinical 
examination because it provides direct visualiza  tion and 
assessment of synovitis, which may be con  sidered a 
surrogate for disease activity. Th   ese researchers examined 
42 joints in each of 97 patients in remission, and compared 
the ultrasound ﬁ  ndings with results from the DAS28 and 
the simpliﬁ  ed disease activity index in the same patients. 
Interestingly, 92 of 97 (95%) patients supposedly in 
remission displayed synovial hypertrophy. Th   ey found that 
the simpliﬁ  ed disease activity index was superior to the 
DAS28 in determining absence of inﬂ  am  matory activity, 
and therefore in determining remission [17].
Th   e American College of Rheumatology (ACR) and the 
European League Against Rheumatism (EULAR) are 
currently preparing a new deﬁ  nition of remission plus 
updated recommendations, and both organizations 
encourage researchers to pursue consensus on a uniform 
deﬁ  nition that may include imaging modalities [14].
Persistent inﬂ  ammation in RA leads to cartilage and 
bone destruction [18]. Inﬂ   ammation and subsequent 
radiological progression drive disability in RA [19]. 
Although the degree of disability varies among patients, 
it is clear that a proportion of patients have disease that 
progresses particularly rapidly. In this patient subset, 
rapid control of inﬂ  ammation is even more important to 
prevent accumulation of permanent damage. Th   e key to 
long-term disease control is therefore achieving prompt 
and substantial control of inﬂ  ammation.
Disease progression is patient specifi  c
It has long been recognized that progression of RA is 
heterogeneous, which means there is high variability in 
progression and disease activity among patients. 
Recognition of patients with rapidly progressing disease 
is critical to identify candidates where intensive therapy 
may have the most impact in terms of preventing disease 
progression and maintaining function. Biological markers 
exist that may be useful in predicting patients at risk for 
active, progressive disease. Markers such as CRP and the 
ESR are extensively used to measure the level or degree 
of inﬂ  ammation in patients with RA [20].
Th  e Persistent Inﬂ   ammatory Symmetrical Arthritis 
(PISA) scoring system has been used in clinical trials to 
establish patients with poor prognosis who are likely to 
have rapidly progressing RA [21]. One point each is 
awarded for rheumatoid factor positivity, for possession 
of the shared epitope (HLA-DR1/DR4/DR10), for a CRP 
level >20  mg/l, for female gender, and for a Health 
Assess  ment Questionnaire raw score >4; and two points 
are awarded for a Health Assessment Questionnaire raw 
score >11. A PISA score ≥3 indicates a poor prognosis 
[21]. Although this test is used in clinical trials to identify 
patients with poor prognoses, it is not clear why the PISA 
system is not practical for routine clinical practice apart 
from the shared epitope with all the other measures that 
are routinely used [22].
In routine clinical practice, several factors have been 
shown to help predict which patients are at risk for 
radiological progression [23,24]. Th   ese biological markers/
clinical indicators include an elevated ESR and CRP level, 
evidence of erosion, number of swollen joints, high DAS 
score, and functional ability using the Health Assessment 
Questionnaire. Autoantibodies, such as rheumatoid 
factor and anti-cyclic citrullinated peptide antibodies, 
also are important predictors of outcome in RA. 
Although these factors are not deﬁ   nitive, if a patient 
exhibits these clinical signs then the physician can be 
conﬁ  dent that, without treatment, the patient is more 
likely to progress rapidly with disability (Table 1).
Patients with rapidly progressing disease require imme-
diate and intensive control of inﬂ  ammation to halt disease. 
Identiﬁ  cation of these patients is therefore impor  tant as it 
oﬀ  ers a greater opportunity to change the course of disease.
Maximizing treatment success in rheumatoid 
arthritis
Classic treatment strategies
Th   e traditional treatment paradigms in RA are based on 
one of two approaches: sequential monotherapy or step-
up combination therapy (Figure 1) [25].
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Page 2 of 10In sequential monotherapy, treatment is initiated with 
traditional disease-modifying antirheumatic drug (DMARD) 
monotherapy, such as MTX. If there is insuﬃ     cient or no 
response, patients are switched to mono  therapy with 
another traditional DMARD, such as sulfasalazine [2]. 
Th   is therapeutic approach may be repeated several times 
until combination therapy with a DMARD plus a biologic 
agent, or with a corticosteroid, is introduced as a last 
resort [2].
In the step-up approach, therapies with the least 
toxicity are utilized early, and more intensive therapies 
are added because of lack of response or toxicity. Patients 
may beneﬁ   t from consultation with physical or 
occupational therapists, social workers, and/or patient 
educators. Nonsteroidal anti-inﬂ  ammatory drugs or local 
low-dose systemic steroids may be considered for control 
of symptoms. Th   e ACR recommends starting treatment 
with a DMARD within 3 months of diagnosis, whereas 
the EULAR recommends that DMARD treatment begins 
as soon as possible [2,26]. DMARDs may be changed or 
added in patients with inadequate response to treatment 
(that is, ongoing active disease after 3 months of maximal 
therapy). Patients who continue to have a suboptimal 
response may be advanced to receive additional trials of 
DMARDs, whether used alone or in combination, or may 
receive treatment with biologic agents [2].
In practice, the frequency of patient visits with a 
rheumatologist is often determined by disease type. 
Patients with rapidly progressing disease are prioritized 
for early review and are seen more often. A pan-European 
survey of rheumatologists (n = 457) established how the 
rheumatologists identify and treat particular patient 
types in everyday practice [27]. Forty percent of respon-
dents reported that they see patients with rapidly pro-
gress  ing disease monthly, whereas only 3% see patients 
with stable disease on a monthly basis. Th  is perceived 
need for assessment of this group allows rheumatologists 
to better achieve treatment goals through identiﬁ  cation 
Table 1. Criteria for identifying the rapidly progressing rheumatoid arthritis patient [5,18-20]
Clinical evidence  Subclinical evidence
Early age of onset  Evidence of erosion on radiograph or MRI (van der Heijde–Sharp score ≥2.6)
Failed two DMARDs in 6 months  Elevated CRP level (≥0.6 mg/dl)
≥4 swollen joints  Elevated ESR (28 mm/hour)
Elevated DAS score (≥4.2) 
Health Assessment Questionnaire raw score >4 
CRP, C-reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; MRI, magnetic resonance 
imaging. Reproduced with permission from Oxford University Press.
Figure 1. Traditional treatment paradigms. DMARD, disease-modifying antirheumatic drug; HCQ, hydroxychloroquine; MTX, methotrexate.
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paradigms such as early use of biologics [27].
Traditional treatments can be suboptimal for patients 
with RA, because these therapies do not fully address the 
underlying inﬂ  ammation driving the disease progression. 
In particular, response to DMARD monotherapy is 
frequently suboptimal, and patients with severe RA 
treated with MTX often exhibit only partial improvement 
[28]. A signiﬁ  cant proportion of patients, however, can 
attain a state of very low disease activity or remission 
with DMARDs [29]. Regardless of studies showing 
DMARD combination therapy to be more eﬀ  ective than 
monotherapy, single-drug treatment remains the initial 
treatment approach for most patients [3]. DMARDs have 
a relatively slow onset of action (1 to 6 months) and may 
have a less favorable side-eﬀ  ect proﬁ  le than some other 
therapies [3,30]. In fact, toxicity is the most common 
reason for discontinuing treatment with MTX [30]. In 
addition, conventional DMARDs, even when used inten-
sively, might be less eﬀ  ective in reducing radiographic 
progression than TNF inhibitors [31]. To meet the RA 
treatment goals of preventing and controlling joint 
damage, preventing disease progression and loss of joint 
function, and improving patients’ QoL, the underlying 
inﬂ   ammation of RA must be rapidly suppressed and 
controlled [2,3].
Biologic agents: addressing unmet needs
DMARDs alone, including the current gold standard 
MTX, do not control disease severity, prevent bone and 
cartilage damage, or maintain QoL in a considerable 
proportion of RA patients [32,33]. Th  e ideal, most 
eﬀ  ective treatment should provide rapid and sustained 
suppression of inﬂ   ammation, resulting in the mainte-
nance of function and prevention of joint damage [5]. In 
patients with well-established RA, biologic agents have 
been shown to eﬀ  ectively improve clinical, functional and 
radiographic outcomes and to retard radiographic 
progres  sion [5,34]. Both the ACR and the EULAR, 
however, currently limit recommendations for addition 
of a biologic to patients with high disease activity and 
poor prognosis in whom the DMARD treatment goal was 
not achieved, and to DMARD-naïve patients with poor 
prognostic markers [29,34]. As is true for any drug, 
biologic agents do not achieve optimal response in all 
patients, and response may diminish over time in some 
patients.
Emerging treatment approaches
Control underlying infl  ammation to prevent disability and 
stop disease progression
Th  e  ﬁ  rst ACR guidelines for the management of RA were 
developed in 1996 and were subsequently updated in 
2002 and 2008 [2,34,35]. Once the initial steps in the 
management of RA – establishing the diagnosis, per-
form  ing a baseline evaluation, and estimating the prog-
nosis [2] – are complete, one must move on to consider 
the optimal treatment strategy for the patient.
Th   e new treatment paradigm recognizes the potential 
window of opportunity for therapeutic intervention in 
early disease. Early therapeutic intervention in RA 
reduces long-term disability and joint damage [6]; the use 
of the most eﬀ  ective therapy is therefore appropriate in 
early treatment [5]. Some studies have evaluated the 
eﬀ  ectiveness of TNF inhibitors (etanercept, adalimumab, 
inﬂ  iximab) in early RA [4,5,36,37].
In the double-blind Combination of Methotrexate and 
Etanercept in Active Early Rheumatoid Arthritis study, 
patients with early RA (disease duration, 3 to 24 months) 
were randomized to receive either MTX plus etanercept 
(50 mg/kg) combination therapy or MTX monotherapy 
[36]. At 52 weeks, 50% (95% conﬁ  dence interval (CI), 44 
to 56%) of patients in the combination treatment group 
achieved clinical remission (DAS28 <2.6) with few 
swollen or tender joints, compared with 28% (95% CI, 23 
to 33%) of patients on MTX monotherapy. Furthermore, 
80% (95% CI, 75 to 85%) of patients in the combination 
treatment group and 59% (95% CI, 53 to 65%) of patients 
in the MTX group achieved radiographic nonprogression 
(modiﬁ  ed total Sharp score change ≤0.5). Th  ese results 
suggest that in addition to achieving an immediate 
improvement in disability, longer-term disability may be 
preventable by inhibiting radiographic progression. Th  e 
study also suggests that remission is an achievable goal in 
patients with early severe RA within the ﬁ   rst year of 
treatment with etanercept plus MTX [36].
Th  e PREMIER study was a randomized, double-blind 
clinical trial comparing the eﬃ   cacy  of  adalimumab 
(40 mg/kg) plus MTX combination therapy versus MTX 
monotherapy or adalimumab monotherapy in patients 
with early RA (disease duration <3 years) [37]. Combi-
nation therapy was superior to both adalimumab and 
MTX mono  therapy in all outcomes in the study. At 
1  year, 43% of patients receiving combination therapy 
achieved clinical remission (DAS28 <2.6), compared with 
23% and 21% of patients receiving adalimumab mono-
therapy and MTX monotherapy, respectively (P <0.001 
for both compari  sons). Following the second year of 
treatment, nearly one-half (49%) of patients receiving 
combi  nation therapy achieved clinical remission, com-
pared with only 25% of patients receiving adalimumab 
monotherapy and 25% of patients receiving MTX mono-
therapy (P <0.001 for both comparisons). Patients receiv-
ing combination therapy demonstrated a mean increase 
in total Sharp score of 1.3 Sharp units, compared with 3.0 
units in those receiving adalimumab monotherapy 
(P = 0.002) and 5.7 units in those receiving MTX mono-
therapy (P <0.001) at 1 year. After 2 years of treatment, 
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have signiﬁ   cantly less radiographic progression (mean 
change, 1.9 Sharp units) compared with those receiving 
either adalimumab monotherapy (5.5 units) or MTX 
monotherapy (10.4 units) (P <0.001 for both compari  sons). 
Th  e study demonstrates the superi  ority of combination 
therapy with adalimumab and MTX over adalimumab 
monotherapy or MTX mono  therapy with respect to 
achieving clinical remission and stopping disease 
progression in patients with early, aggressive RA [37].
In a double-blind study, 20 previously untreated 
patients with early RA (<12  months of symptoms) of 
poor prognosis (PISA scoring system) received either 
MTX plus inﬂ  iximab (3 mg/kg) combination therapy or 
MTX monotherapy for 12  months [5]. Treatment was 
discontinued after 12 months and patients were followed 
for an additional 12 months. Inﬂ  iximab plus MTX treat-
ment was found to reduce magnetic resonance imaging 
(MRI) evidence of synovitis and joint damage compared 
with MTX alone. MRI synovitis scores dropped from 5.5 
at baseline to 3.4 at week 14 in the inﬂ  iximab group, 
compared with a reduction from 6.2 to 5.9 in the MTX-
alone group (P  <0.05). Th  e diﬀ  erence was maintained 
after 12 months of treatment (3.8 vs. 6.6, respectively; 
P <0.05). In the inﬂ  iximab group, rapid improvements in 
physical function were sustained throughout the 
12-month treatment period. Disease activity remained 
below remission levels in 70% of patients 12 months after 
the withdrawal of therapy. Similar beneﬁ  ts were seen in 
QoL. Th  ese results suggest that the rapid control of 
inﬂ  ammation demonstrated by inﬂ  iximab confers long-
term functional, QoL, and MRI beneﬁ  ts [5].
Th  is study by Quinn and colleagues also shows that 
CRP levels rapidly return to normal levels in patients 
receiving inﬂ   iximab combination therapy. Indeed, a 
single inﬂ  iximab infusion normalizes mean CRP levels 
(Figure 2). Th   e reduction in CRP is signiﬁ  cantly greater in 
the inﬂ   iximab group compared with the MTX-alone 
group (P  <0.05) and corresponds with suppression of 
inﬂ  ammatory joint disease (MRI synovitis) and resultant 
prevention of structural damage (MRI erosions) [5].
In the Tight Control of RA study, intensive manage-
ment with conventional DMARDs, an intra-articular 
steroid, and frequent clinical assessments was compared 
with routine outpatient care [31]. Th   e primary outcome 
measures were a mean decrease in the DAS and in the 
proportion of patients with a good response. Th  e mean 
decrease in the DAS was greater in the intensive group 
than in the routine group (–3.5 vs. –1.9; 95% CI, 1.1 to 
1.2; P <0.0001). Additionally, patients treated intensively 
were more likely to have a good response (45/55 (82%) vs. 
24/55 (44%); 95% CI, 2.4 to 13.9; P <0.0001) or to be in 
remission deﬁ   ned by DAS <1.6 (36/55 (65%) vs. 9/55 
(16%); 95% CI, 3.9 to 23.9; P <0.001). Th   e Tight Control of 
RA study showed that a strategy of intensive outpatient 
management substantially improves disease activity, 
radiographic disease progression, physical function, and 
QoL at no additional cost [31].
Figure 2. Infl  iximab rapidly normalizes C-reactive protein levels in rheumatoid arthritis [5]. AUC, area under the curve; CRP, C-reactive 
protein; MTX, methotrexate. Reproduced with permission from [5].
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disease-management decisions is also illustrated by the 
BeSt study [4]. Pisetsky oﬀ  ers some very real conclusions 
in his ‘provocative and very creative’ [38] landmark 
randomized clinical trial on treatment strategies for RA 
[39]. Treatment adjustments were made every 3 months 
in an eﬀ  ort to obtain low disease activity (DAS in 44 
joints (DAS44) ≤2.4) and may be described as DAS-
driven therapy [7]. Previous data have indicated that 
treatment with a DMARD such as MTX combined with a 
TNF inhibitor is more eﬀ  ective than DMARD mono-
therapy [4]. Th  e anti-TNF therapy (inﬂ  iximab) used in 
the BeSt study also has a rapid onset of action (as early as 
2 weeks) [2], a favorable safety proﬁ   le, and sustained 
eﬀ  ects in many RA patients [4].
Th   e development of TNF inhibitors presents clinicians 
with eﬀ  ective treatment options. Th  e increase in thera-
peutic choices, however, leaves open the question of what 
is the optimal therapeutic strategy in patients presenting 
with RA. In an attempt to answer this question, the BeSt 
study compared the clinical and radiographic outcomes 
of four diﬀ  erent treatment strategies: sequential mono-
therapy; step-up combination therapy; initial combina-
tion therapy with tapered high-dose prednisone; and 
initial combination therapy with inﬂ  iximab  (Figure  3). 
Th  e common goal in all strategies was to rapidly and 
eﬀ  ectively reduce disease activity by tight monitoring and 
immediate adjustment of therapy in the case of an 
insuﬃ   cient response [4]. Th  e BeSt study is the ﬁ  rst in 
which decisions about changing the dosage or discon-
tinuing inﬂ   iximab treatment were dictated by DAS 
calculations before every infusion [40]. It is possible that 
some conclusions drawn from this study may be 
extrapolated to all TNF inhibitors.
Th  e  speciﬁ  c objective for each treatment group in the 
BeSt study was to reach and sustain a DAS44 ≤2.4, 
indicating low disease activity. After 1 year, this goal was 
attained by 53% of patients on sequential monotherapy 
(P = 0.004 vs. prednisone; P = 0.001 vs. inﬂ  iximab), by 
64% on step-up combination therapy, by 71% on initial 
combination therapy with tapered high-dose prednisone, 
and by 74% on initial combination therapy with inﬂ  ixi-
mab (Figure 4) [4].
Patients treated with initial combination therapy, with 
either prednisone or inﬂ  iximab, had greater and more 
rapid functional improvement than patients treated with 
sequential monotherapy or step-up combination therapy. 
Additionally, clinical improvement measured by ACR 
response criteria was achieved earlier and by a greater 
number of patients treated with initial combination 
therapy than in the other two groups [4].
After 1 year, patients treated with initial combination 
therapy had signiﬁ  cantly less progression of radiographic 
joint damage (prednisone, 87%; inﬂ   iximab, 93%) than 
those treated with sequential monotherapy (67%) or step-
up combination therapy (73%) (P <0.001 sequential vs. 
prednisone and inﬂ  iximab; P = 0.010 step-up vs. predni-
sone; P <0.001 step-up vs. inﬂ  iximab; P = not signiﬁ  cant 
for other comparisons) [4].
Th   e patients in each group did not necessarily remain in 
their initial treatment protocol since treatment was 
adjusted every 3 months in patients who did not reach and 
sustain DAS44 ≤2.4. In the sequential monotherapy group, 
approximately 50% of patients required treatment 
adjustment and 67% of patients had no progression or 
radiographic joint damage, suggesting that the initial time 
of 3 months on MTX monotherapy is too long to prevent 
erosion. Conversely, 93% of patients receiving inﬂ  iximab 
initially have no progression of joint damage [4].
Four years after starting combination treatment with 
inﬂ  iximab and MTX, 51% (61/120) of the patients with 
very early RA had discontinued inﬂ  iximab and still had 
DAS44 ≤2.4. Of these 61 patients that were oﬀ   inﬂ  iximab 
treatment at year 4, 17% (20/120) remained in clinical 
remission (DAS44 <1.6 for ≥6 months) after stopping all 
antirheumatic drugs without showing progression of 
joint damage (Figure  5). Additionally, those 17% of 
patients receiving initial inﬂ  iximab combination therapy 
had discontinued all antirheumatic drugs and achieved 
clinical remission. Radiographic progression was highest 
in patients who had failed MTX and inﬂ  iximab treat-
ment, and was minimal in those 20 patients who discon-
tinued all antirheumatic therapy (Figure 6) [41].
At 5 years, up to 51% of patients achieved remission 
(DAS <1.6) after sequential monotherapy treatment. Of 
those remissions, 39% of patients remained on initial 
sequential monotherapy and 81% remained on the initial 
allocation to combination treatment with inﬂ  iximab 
(P <0.001 vs. sequential monotherapy). Overall, 48% of all 
patients achieved remission and up to 19% achieved drug-
free remission. Initial treatment of patients with early, 
active RA with inﬂ  iximab and MTX oﬀ  ers the opportunity 
to discontinue inﬂ  iximab in the majority of patients once a 
low DAS is achieved and maintained without ﬂ  are of the 
disease. Additionally, a low dosage of MTX may maintain a 
low level of disease activity in most responders [40].
Figure 3. Four treatment strategies of the BeSt analysis [4].
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Page 6 of 10Figure 4. Clinical outcomes in the BeSt study. Error bars indicate 95% confi  dence intervals. DAS44, disease activity score in 44 joints (DAS44 ≤2.4 
indicates adequate clinical response; DAS44 <1.6 indicates clinical remission). ACR20/ACR70, 20%/70% improvement according to the American 
College of Rheumatology response criteria [4]. HAQ, Health Assessment Questionnaire. Reproduced with permission from [4].
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suppression of RA activity with a TNF inhibitor may 
provide earlier clinical improvement and less progression 
of joint damage. Furthermore, the use of initial combi-
nation therapy does not result in increased toxicity. 
Additionally, combination therapy can be withdrawn 
successfully and less treatment adjustments are needed 
than with initial monotherapies. Th  is cooperative study 
in an organized healthcare setting demonstrated that 
there appears to be an opportunity for patients initially 
diagnosed with RA to achieve a lasting beneﬁ  t in the 
course of their disease. Furthermore, true clinical remis-
sion without any continuing or ongoing mainte  nance 
therapy may even be possible [42].
In terms of selection of therapy, the most recent ACR 
guidelines recommend use of TNF inhibitors in 
DMARD-näive patients with early RA and high disease 
activity. Combination treatment of a TNF inhibitor plus 
MTX is recommended if high disease activity is present 
for 3 to 6 months or for <3 months with features of a 
poor prog  nosis (plus reimbursement-related qualiﬁ  ca-
tions) [34]. Current EULAR guidelines recommend use 
of TNF inhibi  tors when the initial DMARD-alone 
strategy has failed and poor prognostic factors (that is, 
autoantibodies, high disease activity, early erosions) are 
present [29].
Data from the BeSt study indicate that initial treatment 
with inﬂ  iximab plus MTX results in signiﬁ  cantly better 
functional ability over 5 years than other treatment 
strategies [7]. In addition, inﬂ   iximab provides rapid 
disease control with corresponding suppression of 
inﬂ  am  matory disease resulting in functional, QoL, and 
MRI damage beneﬁ  ts [5]. Th   e early use of TNF inhibitors 
may have a speciﬁ  c eﬀ  ect on the processes that sustain 
underlying inﬂ  ammation [5].
As part of any treatment decision process, one must 
consider both the beneﬁ  ts as well as possible safety risks. 
Additionally, patient-speciﬁ   c parameters need to be 
considered when selecting a treatment strategy. One such 
treatment strategy can include early intensive treatment 
with biologic therapy. Th  ere are safety considerations 
with the use of biologics such as TNF inhibitors, which 
include risk of infections, lymphoma, and infusion-site or 
injection-site reactions. Patients should be monitored 
regularly for potential safety issues while being treated 
with a TNF inhibitor.
In the BeSt study, no signiﬁ  cant diﬀ  erences were found 
in the number of adverse events and withdrawals 
between the groups during the ﬁ  rst 12 months [4]. In 
particular, no cases of tuberculosis or opportunistic 
infec  tions were reported [4]. In clinical studies with 
inﬂ   ixi  mab, adverse reactions are observed in approxi-
mately 60% of inﬂ   iximab-treated patients and 40% of 
placebo-treated patients. Infusion-related reactions are 
the most common adverse reactions reported, and 
dyspnea, urticaria, and headache are the most common 
causes of discontinuation [43].
Clinical practice is beginning to change as a result of a 
paradigm shift that incorporates the increased use of 
TNF inhibitor treatment strategies. Optimal treatment of 
patients with RA requires comprehensive coordinated 
care and the expertise of a number of healthcare 
providers. Proper identiﬁ  cation of patients with active, 
progressive disease is important; early intervention 
therefore oﬀ  ers a tremendous opportunity to change the 
course of disease and avoid the serious consequences of 
disease progression [2,26]. At each follow-up visit, the 
disease must be assessed as being active or inactive. 
Tracking disease progression can be diﬃ   cult,  and 
patients at risk for active, progressive disease may go 
undetected. Occasionally, joint examination alone may 
not adequately reﬂ   ect disease activity and structural 
damage; periodic measurements of other factors that 
may be predictive of radiological progression can there-
fore be assessed in routine clinical practice. Such factors 
include the ESR or CRP level and functional status as well 
as radiographic examinations of involved joints. Intensive 
Figure 5. Some patients enter complete remission with 
combination therapy [41]. DAS44, disease activity score in 44 joints.
Off infliximab:  51% (61/120) 
Patients in clinical remission 
(DAS44 <1 6 f 6t h )
17% n=41
After 4 years
(DAS44 <1.6 for 6 months)
• Off infliximab
• No antirheumatic drugs After 4 years
120 Patients
n=22
No antirheumatic drugs
• No progression of joint 
damage
n=22
n=30
Failed infliximab: 25% (30/120)
On infliximab: 18% (22/120)
Failed infliximab:  25% (30/120) 
On infliximab:  18% (22/120)
Figure 6. Less radiographic progression with infl  iximab 
combination therapy [41]. SHS, Sharp–van der Hiejde score.
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has the ability to improve patient outcomes and may 
prevent irreversible joint damage [2,26].
Equally important is identiﬁ  cation of patients who will 
respond optimally to biologic agents and/or to early 
intensive therapy. Evidence suﬃ   cient to support predic-
tors of response, however, is lacking [29,44,45].
Conclusions
Th  e underlying inﬂ  ammation that is critical for disease 
progression in chronic inﬂ  ammatory diseases such as RA 
is not fully treated with traditional therapies. As conven-
tional nonbiologic monotherapy is the ﬁ  rst  treatment 
oﬀ  ered to the majority of patients, it is clear that most 
patients are suboptimally or undertreated for RA. 
Important treatment goals in RA patients include achiev-
ing remission, prevention and control of joint damage, 
avoidance of further disease progression and loss of joint 
function, and improvement in QoL. In order to meet 
these challenges, the underlying inﬂ   ammation of RA 
must be rapidly suppressed and controlled [2,3].
Accumulating data show that intensive treatment 
strategies with biologic agents, especially the TNF inhibi-
tors (that is, inﬂ  iximab), is more eﬀ  ective than sequential 
monotherapy or step-up combination therapy and should 
be adopted early in the course of RA [4]. TNF inhibitors 
show substantial eﬃ     cacy in combination with MTX, 
providing rapid and substantial beneﬁ  t and improvement 
in patient outcomes.
In addition to the importance of understanding the 
eﬃ   cacy and safety proﬁ   le of a particular drug in RA, 
recognizing the optimal treatment paradigm in which 
that drug ﬁ  ts is equally essential. Times are changing, and 
both our understanding of disease processes and the 
availa  bility of new therapies also drive us to change our 
practice. In everyday practice, we now have ways to 
identify those patients who are at risk for more rapid 
disease progres  sion and the ability to choose to treat 
these patients more intensively with biologic therapy. In 
doing this, the evidence suggests we will best prevent the 
long-term disability eﬀ  ects of RA for our patients.
Abbreviations
ACR, American College of Rheumatology; BeSt, Behandel-Strategieën; CI, 
confi  dence interval; CRP, C-reactive protein; DAS, disease activity score; DAS28, 
disease activity score in 28 joints; DAS44, DAS in 44 joints; DMARD, disease-
modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; EULAR, 
European League Against Rheumatism; MRI, magnetic resonance imaging; 
MTX, methotrexate; PISA, Persistent Infl  ammatory Symmetrical Arthritis; QoL, 
quality of life; RA, rheumatoid arthritis; TNF, tumor necrosis factor.
Competing interests
FCB has received speaker fees from Pfi  zer, Abbott, Centocor, Wyeth and 
Schering-Plough. BC has been a speaker and/or consultant for Abbott, BMS, 
MSD, Roche, Schering-Plough, UCB and Wyeth.
Acknowledgements
Merck, Sharp & Dohme Corporation (Whitehouse Station, NJ, USA) provided 
fi  nancial support for this article. Synergy Medical Education (Conshohocken, 
PA, USA) assisted in the preparation of the manuscript.
This article is part of Arthritis Research & Therapy Volume 13 Supplement 1: The 
evolution on anti-TNF therapy in rheumatic disease: experience, insights and 
advances. The full contents of the supplement are available online at 
http://arthritis-research.com/supplements/13/S1. Publication of this 
supplement is sponsored by Merck, Sharp & Dohme Corporation, 
Whitehouse Station, New Jersey, USA.
Author details
1Department of Rheumatology, Leiden University Medical Center, C1-39, 
PO Box 9600, 2300 RC Leiden, The Netherlands. 2Immuno-Rhumatologie, 
Hopital Lapeyronie, CHU Montpellier, Université Montpellier 1, Montpellier 
F-34000, France.
Published: 25 May 2010
References
1.  Emery P, Seto Y: Role of biologics in early arthritis. Exp Rheumatol 2003, 
21(Suppl 30):S191-S194.
2.  American College of Rheumatology Subcommittee on Rheumatoid Arthritis 
Guidelines: Guidelines for the management of rheumatoid arthritis. 2002 
update. Arthritis Rheum 2002, 46:328-346.
3.  Chen S, Gill MA, Luu CH, Takami S: Pain and rheumatoid arthritis: an update. 
Drug Topics 2000, April 3:47-56.
4.  Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, 
Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, 
Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, 
Dijkmans BA: Clinical and radiographic outcomes of four diff  erent 
strategies in patients with early rheumatoid arthritis (the BeSt study). 
A randomized controlled trial. Arthritis Rheum 2005, 52:3381-3390.
5.  Quinn MA, Conaghan PG, O’Connor PJ, Karim Z, Greenstein A, Brown A, 
Brown C, Fraser A, Jarret S, Emery P: Very early treatment with infl  iximab in 
addition to methotrexate in early, poor-prognosis rheumatoid arthritis 
reduces magnetic resonance imaging evidence of synovitis and damage, 
with sustained benefi  t after infl  iximab withdrawal. Results from a twelve-
month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 
2005, 52:27-35.
6.  Quinn MA, Conaghan PG, Emery P: The therapeutic approach of early 
intervention for rheumatoid arthritis: what is the evidence? Rheumatology 
2001, 40:1211-1220.
7.  Klarenbeek, NB, Güler-Yüksel M, van der Kooij SM, van der Heijde DMFM, 
Huizinga TWJ, Kerstens PJMS, Peeters AJ, Ronday HK, Westedt ML, Dijkmans 
BAC, Allaart CF: Clinical outcomes of four diff  erent treatment strategies in 
patients with recent-onset rheumatoid arthritis: 5-year results of the BeSt 
Study [abstract]. Ann Rheum Dis 2008, 67(Suppl II):187.
8.  Arvidsson NG, Gubjornsson B, Hallgren R, Larrson A: Concordant message of 
diff  erent infl  ammatory markers in patients with rheumatoid arthritis. Ups J 
Med Sci 1998, 103:35-42.
9.  Whicher JT, Dieppe PA: Acute phase proteins. Clin Immunol Allergy 1985, 
5:425-446.
10.  Mallya RK, de Beer FC, Berry H, Hamilton ED, Mace BE, Pepys MB: Correlation 
of clinical parameters of disease activity in rheumatoid arthritis with 
serum concentrations of C-reactive protein and erythrocyte 
sedimentation rate. J Rheumatol 1982, 9:224-228.
11. Otterness  IG:  The value of C-reactive protein measurement in rheumatoid 
arthritis. Semin Arthritis Rheum 1994, 24:91-104.
12.  Dessein PH, Joff  e BI, Stanwix AE: High sensitivity C-reactive protein as a 
disease activity marker in rheumatoid arthritis. J Rheumatol 2004, 
31:1095-1097.
13.  Skogh T, Gustafsson D, Kjellberg M, Husberg M: Twenty eight joint count 
disease activity score in recent onset rheumatoid arthritis using C reactive 
protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 2003, 
62:681-682.
14.  Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, 
Bombardier S, Choi H, Dougados M, Emery P, Gomez-Reino J, Keystone E, 
Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O’Dell J, 
Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen, JS, Sokka T, Strand 
GV, Tugwell P, van der Heijde D, van Riel P, et al.: Reporting disease activity in 
clinical trials of patients with rheumatoid arthritis: EULAR/ACR 
collaborative recommendations. Ann Rheum Dis 2008, 67:1360-1364.
15.  Dougados M, Aletaha D, van Riel P: Disease activity measures for 
rheumatoid arthritis. Clin Exp Rheumatol 2007, 25(Suppl 46):S22-S29.
Breedveld and Combe Arthritis Research & Therapy 2011, 13(Suppl 1):S3 
http://arthritis-research.com/supplements/13/S1/S3
Page 9 of 1016. Salaffi    F, Cimmino MA, Leardini G, Gasparini S, Grassi W; Epidemiology Study 
Group of the Italian Society of Rheumatology: Disease activity assessment 
of rheumatoid arthritis in daily practice: validity, internal consistency, 
reliability, and congruency of the disease activity score including 28 joints 
compared with the clinical disease activity index. Clin Exp Rheumatol 2009, 
27:552-559.
17.  Balsa A, de Miguel E, Castillo C, Peiteado D, Martín-Mola E: Superiority of 
SDAI over DAS-28 in assessment of remission in rheumatoid arthritis 
patients using power Doppler ultrasonography as a gold standard. 
Rheumatology 2010, 49:683-690.
18.  Choy EH, Panayi GS: Cytokine pathways and joint infl  ammation in 
rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
19. Kirwan  JR:  Links between radiological change, disability, and pathology in 
rheumatoid arthritis. J Rheumatol 2001, 28:881-886.
20.  Garnero P, Geusens P, Landewé R: Biochemical markers of joint tissue 
turnover in early rheumatoid arthritis. Clin Exp Rheumatol 2003, 
21(5 Suppl 31):S54-S58.
21. Emery  P:  The Dunlop–Dottridge Lecture: prognosis in infl  ammatory 
arthritis: the value of HLA genotyping and the oncological analogy. 
J Rheumatol 1997, 24:1436-1442.
22.  Emery P, McInnes IB, van Vollenhoven R, Kraan MC: Clinical identifi  cation and 
treatment of a rapidly progressing disease state in patients with 
rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:392-398.
23.  Smolen J, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, 
Maini RN, Kalden JR, Schiff   M, Baker D, Han C, Han J, Bala M; Active-Controlled 
Study of Patients Receiving Infl  iximab for the Treatment of Rheumatoid 
Arthritis of Early Onset (ASPIRE) Study Group: Predictors of joint damage in 
patients with early rheumatoid arthritis treated with high-dose 
methotrexate with or without concomitant infl  iximab: results from the 
ASPIRE trial. Arthritis Rheum 2006, 54:702-710.
24.  Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM: How to diagnose 
rheumatoid arthritis early: a prediction model for persistent (erosive) 
arthritis. Arthritis Rheum 2002, 46:357-365.
25. Mitka  M:  Early rheumatoid arthritis treatments weighed. JAMA 2005, 
294:3073-3074.
26.  Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, Emery 
P, Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen H, 
Silman A, Smolen J, Yazici H: EULAR recommendations for the management 
of early arthritis: report of a task force of the European Standing 
Committee for International Clinical Studies Including Therapeutics 
(ESCISIT). Ann Rheum Dis 2007, 66:34-45.
27. McInnes  IB:  Attitudes of rheumatologists to rapidly progressing 
rheumatoid arthritis [abstract]. Rheumatology 2007, 6(Suppl 1):i89.
28.  Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful 
thinking or clinical reality? Semin Arthritis Rheum 2005, 35:185-196.
29.  Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, 
Gorter S, Knevel R, Nam J, Schoels M, Aleteha D, Buch M, Gossec L, Huizinga T, 
Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomex-Reino J, 
Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, 
Schholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, et al.: EULAR 
recommendations for the management of rheumatoid arthritis with 
synthetic and biological disease-modifying antirheumatic drugs. Ann 
Rheum Dis 2010, 69:964-975.
30. Keystone  EC:  The role of tumor necrosis factor antagonism in clinical 
practice. J Rheumatol 1999, 26(Suppl 57):22-28.
31.  Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, 
Porter D: Eff  ect of a treatment strategy of tight control for rheumatoid 
arthritis (the TICORA study): a single-blind randomised controlled trial. 
Lancet 2004, 364:263-269.
32. Odeh  M:  New insights into the pathogenesis and treatment of rheumatoid 
arthritis. Clin Immunol Immunopathol 1997, 83:103-116.
33. Weinblatt  ME:  The role of current strategies in the future treatment of 
rheumatoid arthritis. Rheumatology (Oxford) 1999, 38(Suppl 2):19-23.
34.  Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, 
Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, 
Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, 
O’Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology: 
American College of Rheumatology 2008 recommendations for the use of 
non-biologic and biologic disease-modifying antirheumatic drugs in 
rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
35.  American College of Rheumatology, Ad Hoc Committee on Clinical 
Guidelines: Guidelines for the management of rheumatoid arthritis. 
Arthritis Rheum 1996, 39:713-722.
36.  Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, 
Pedersen RD, Koenig AS, Freundlich B: Comparison of methotrexate 
monotherapy with a combination of methotrexate and etanercept in 
active, early, moderate to severe rheumatoid arthritis (COMET): 
a randomised, double-blind, parallel treatment trial. Lancet 2008, 
372:375-382.
37.  Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van 
Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT: The PREMIER study: 
a multicenter, randomized, double-blind clinical trial of combination 
therapy with adalimumab plus methotrexate versus methotrexate alone 
or adalimumab alone in patients with early aggressive rheumatoid 
arthritis who had not had previous methotrexate treatment. Arthritis 
Rheum 2006, 54:26-37.
38. Weisman  MH:  Progress toward the cure of rheumatoid arthritis? The BeSt 
study. Arthritis Rheum 2005, 52:3326-3332.
39. Pisetsky  DS:  A landmark study on treatment strategies for rheumatoid 
arthritis. Arthritis Rheum 2008, 58(2 Suppl):S123-S125.
40.  van der Bijl AE, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Ten Wolde S, 
Han KH, van Krugten MV, Allaart CF, Breedveld FC, Dijkmans BA: Infl  iximab 
and methotrexate as induction therapy in patients with early rheumatoid 
arthritis. Arthritis Rheum 2007, 56:2129-2134.
41.  van der Kooij SM, Goekoop-Ruiterman YP, De Vries-Bouwstra JK, Guler-Yuksel 
M, Zwinderman AH, Kerstens PJ, Van Der Lubbe PA, De Beus WM, Grillet BA, 
Ronday K, Huizinga TW, Breedveld FC, Dijkmans BA, Allaart CF: Drug-free 
remission, functioning and radiographic damage after 4 years of 
response-driven treatment in patients with recent onset rheumatoid 
arthritis. Ann Rheum Dis 2008, 68:914-921.
42.  Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, 
Kerstens PJ, Hazes JM, Zwinderman AH, Peeters AJ, de Jonge-Bok JM, Mallée 
C, de Beus WM, de Sonnaville PB, Ewals JA, Breedveld FC, Dijkmans BA: 
Comparison of treatment strategies in early rheumatoid arthritis. 
A randomized trial. Ann Intern Med 2007, 146:406-415.
43.  Schering-Plough. Remicade SPC, 2009 [http://emc.medicines.org.uk/emc/
assets/c/html/DisplayDoc.asp?DocumentID=3236#TOP]
44.  Hyrich KL, Watson KD, Silman AJ, Symmons DPM; BSR Biologics Register: 
Predictors of response to anti-TNF-α therapy among patients with 
rheumatoid arthritis: results from the British Society for Rheumatology 
Biologics Register. Rheumatology 2006, 45:1558-1565.
45.  Plenge RM, Criswell LA: Genetic variants that predict response to anti-
tumor necrosis factor therapy in rheumatoid arthritis: current challenges 
and future directions. Curr Opin Rheumatol 2008, 20:145-152.
doi:10.1186/ar3093
Cite this article as: Breedveld FC, Combe B: Understanding emerging 
treatment paradigms in rheumatoid arthritis. Arthritis Research & Therapy 
2011, 13(Suppl 1):S3.
Breedveld and Combe Arthritis Research & Therapy 2011, 13(Suppl 1):S3 
http://arthritis-research.com/supplements/13/S1/S3
Page 10 of 10